Immunology of HIV-Associated Kaposi Sarcoma



An epidemic of Kaposi’s sarcoma (KS) among severely immunocompromised men heralded the beginning of the HIV pandemic in 1981, and since that time considerable efforts have gone into understanding the role of the human immune system in the control of KS tumorigenesis. Infection with human herpesvirus-8 (HHV-8), the etiologic agent of KS, is necessary but not sufficient for the development of the tumor. In this chapter, we review what is known about innate and adaptive cellular immunity to HHV-8 and KS, and consider host, viral and environmental factors which may predispose to the development of KS from chronic HHV-8 infection. Finally, we review the epidemiology of KS in the era of highly active antiretroviral therapy (HAART), where both a dramatic decrease in the incidence of KS but also a newly recognized immune reconstitution inflammatory syndrome (IRIS) has been recognized. In this context, we consider the impact of HAART on the clinical manifestations and natural history of KS.


Immune Reconstitution Immune Reconstitution Inflammatory Syndrome Immune Reconstitution Inflammatory Syndrome Event 



Grant Support: NIH grants K23 AI054162, P01 AI027757, P01 CA18029 and U01 CA111273, Clinical Scientist Development Award from the Doris Duke Charitable Foundation, and the University of Washington/Fred Hutchinson Cancer Research Center Center for AIDS Research


  1. (1992). 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 41(RR-17), 1–19.Google Scholar
  2. (2002). Cancer incidence in five continents. Volume VIII. IARC Sci Publ 155, 1–781.Google Scholar
  3. (2007). Surveillance, Epidemiology, and End Results (SEER) Program SEER*Stat Database: Incidence – SEER 9 Regs Limited-Use, Nov 2006 Sub (1973–2004), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch.Google Scholar
  4. Ambrosino, C., Ruocco, M. R., et al. (1997). HIV-1 Tat induces the expression of the interleukin-6 (IL6) gene by binding to the IL6 leader RNA and by interacting with CAAT enhancer-binding protein beta (NF-IL6) transcription factors. J Biol Chem 272(23), 14883–14892.PubMedGoogle Scholar
  5. Aoki, Y., and Tosato, G. (2004). HIV-1 Tat enhances Kaposi sarcoma-associated herpesvirus (KSHV) infectivity. Blood 104(3), 810–814.PubMedGoogle Scholar
  6. Archibald, C. P., Schechter, M. T., et al. (1990). Risk factors for Kaposi’s sarcoma in the Vancouver Lymphadenopathy–AIDS Study. J Acquir Immune Defic Syndr 3(Suppl 1), S18–S23.PubMedGoogle Scholar
  7. Archibald, C. P., Schechter, M. T., et al. (1992). Evidence for a sexually transmitted cofactor for AIDS-related Kaposi’s sarcoma in a cohort of homosexual men. Epidemiology 3(3), 203–209.PubMedGoogle Scholar
  8. Armenian, H. K., Hoover, D. R., et al. (1993). Composite risk score for Kaposi’s sarcoma based on a case–control and longitudinal study in the Multicenter AIDS Cohort Study (MACS) population. Am J Epidemiol 138(4), 256–265.PubMedGoogle Scholar
  9. Ascoli, V., Belli, S., et al. (2001). High incidence of classic Kaposi’s sarcoma in Mantua, Po Valley, Northern Italy (1989–1998). Br J Cancer 85(3), 379–382.PubMedGoogle Scholar
  10. Autran, B., Carcelain, G., et al. (1997). Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 277(5322), 112–116.PubMedGoogle Scholar
  11. Bani-Sadr, F., Fournier, S., et al. (2003). Relapse of Kaposi’s sarcoma in HIV-infected patients switching from a protease inhibitor to a non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy regimen. AIDS 17(10), 1580–1581.PubMedGoogle Scholar
  12. Barillari, G., Gendelman, R., et al. (1993). The Tat protein of human immunodeficiency virus type 1, a growth factor for AIDS Kaposi sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD amino acid sequence. Proc Natl Acad Sci USA 90(17), 7941–7945.PubMedGoogle Scholar
  13. Beral, V., Bull, D., et al. (1992). Risk of Kaposi’s sarcoma and sexual practices associated with faecal contact in homosexual or bisexual men with AIDS. Lancet 339(8794), 632–635.PubMedGoogle Scholar
  14. Bhaskaran, K., Hamouda, O., et al. (2008). Changes in the risk of death after HIV seroconversion compared with mortality in the general population. J Am Med Assoc 300(1), 51–59.Google Scholar
  15. Biggar, R. J., Chaturvedi, A. K., et al. (2007). AIDS-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst 99(12), 962–972.PubMedGoogle Scholar
  16. Bihl, F., Mosam, A., et al. (2007). Kaposi’s sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi’s sarcoma. AIDS 21(10), 1245–1252.PubMedGoogle Scholar
  17. Birkeland, S. A., Storm, H. H., et al. (1995). Cancer risk after renal transplantation in the Nordic countries, 1964–1986. Int J Cancer 60(2), 183–189.PubMedGoogle Scholar
  18. Blum, L., Pellet, C., et al. (1997). Complete remission of AIDS-related Kaposi’s sarcoma associated with undetectable human herpesvirus-8 sequences during anti-HIV protease therapy. AIDS 11(13), 1653–1655.PubMedGoogle Scholar
  19. Bourboulia, D., Aldam, D., et al. (2004). Short- and long-term effects of highly active antiretroviral therapy on Kaposi sarcoma-associated herpesvirus immune responses and viraemia. AIDS 18(3), 485–493.PubMedGoogle Scholar
  20. Bower, M., Nelson, M., et al. (2005). Immune reconstitution inflammatory syndrome associated with Kaposi’s sarcoma. J Clin Oncol 23(22), 5224–5228.PubMedGoogle Scholar
  21. Bower, M., Powles, T., et al. (2007). Brief communication: rituximab in HIV-associated multicentric Castleman disease. Ann Intern Med 147(12), 836–839.PubMedGoogle Scholar
  22. Broccolo, F., Bossolasco, S., et al. (2002). Detection of DNA of lymphotropic herpesviruses in plasma of human immunodeficiency virus-infected patients: frequency and clinical significance. Clin Diagn Lab Immunol 9(6), 1222–1228.PubMedGoogle Scholar
  23. Brown, E. E., Fallin, D., et al. (2006a). Associations of classic Kaposi sarcoma with common variants in genes that modulate host immunity. Cancer Epidemiol Biomarkers Prev 15(5), 926–934.PubMedGoogle Scholar
  24. Brown, E. E., Fallin, M. D., et al. (2006b). Host immunogenetics and control of human herpesvirus-8 infection. J Infect Dis 193(8), 1054–1062.PubMedGoogle Scholar
  25. Brown, E. E., Whitby, D., et al. (2006c). Virologic, hematologic, and immunologic risk factors for classic Kaposi sarcoma. Cancer 107(9), 2282–2290.PubMedGoogle Scholar
  26. Burnet, F. M. (1970). The concept of immunological surveillance. Prog Exp Tumor Res 13, 1–27.PubMedGoogle Scholar
  27. Camcioglu, Y., Picard, C., et al. (2004). HHV-8-associated Kaposi sarcoma in a child with IFNgammaR1 deficiency. J Pediatr 144(4), 519–523.PubMedGoogle Scholar
  28. Camera Pierrotti, L., Masami Sumita, L., et al. (2000). Detection of human herpesvirus 8 DNA and antibodies to latent nuclear and lytic-phase antigens in serial samples from aids patients with Kaposi’s sarcoma. J Clin Virol 16(3), 247–251.PubMedGoogle Scholar
  29. Campbell, T. B., Borok, M., et al. (2000). Relationship of human herpesvirus 8 peripheral blood virus load and Kaposi’s sarcoma clinical stage. AIDS 14(14), 2109–2116.PubMedGoogle Scholar
  30. Cannon, M. J., Dollard, S. C., et al. (2003). Risk factors for Kaposi’s sarcoma in men seropositive for both human herpesvirus 8 and human immunodeficiency virus. AIDS 17(2), 215–222.PubMedGoogle Scholar
  31. Casper, C., and Wald, A. (2007). The use of antiviral drugs in the prevention and treatment of Kaposi sarcoma, multicentric Castleman disease and primary effusion lymphoma. Curr Top Microbiol Immunol 312, 289–307.PubMedGoogle Scholar
  32. Cattelan, A. M., Calabro, M. L., et al. (1999). Regression of AIDS-related Kaposi’s sarcoma following antiretroviral therapy with protease inhibitors: biological correlates of clinical outcome. Eur J Cancer 35(13), 1809–1815.PubMedGoogle Scholar
  33. Chokunonga, E., Levy, L. M., et al. (1999). Aids and cancer in Africa: the evolving epidemic in Zimbabwe. AIDS 13(18), 2583–2588.PubMedGoogle Scholar
  34. Connick, E., Kane, M. A., et al. (2004). Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma during potent antiretroviral therapy. Clin Infect Dis 39(12), 1852–1855.PubMedGoogle Scholar
  35. Contu, L., Cerimele, D., et al. (1984). HLA and Kaposi’s sarcoma in Sardinia. Tissue Antigens 23(4), 240–245.PubMedGoogle Scholar
  36. Cottoni, F., Masala, M. V., et al. (1997). The role of occupation and a past history of malaria in the etiology of classic Kaposi’s sarcoma: a case–control study in north-east Sardinia. Br J Cancer 76(11), 1518–1520.PubMedGoogle Scholar
  37. Crane, H. M., Deubner, H., et al. (2005). Fatal Kaposi’s sarcoma-associated immune reconstitution following HAART initiation. Int J STD AIDS 16(1), 80–83.PubMedGoogle Scholar
  38. Deayton, J. R., Sabin, C. A., et al. (2002). Rapid reconstitution of humoral immunity against cytomegalovirus but not HIV following highly active antiretroviral therapy. AIDS 16(16), 2129–2135.PubMedGoogle Scholar
  39. DeSimone, J. A., Pomerantz, R. J., et al. (2000). Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy. Ann Intern Med 133(6), 447–454.PubMedGoogle Scholar
  40. Dukers, N. H., and Rezza, G. (2003). Human herpesvirus 8 epidemiology: what we do and do not know. AIDS 17(12), 1717–1730.PubMedGoogle Scholar
  41. Dunn, G. P., Old, L. J., et al. (2004). The three Es of cancer immunoediting. Annu Rev Immunol 22, 329–360.PubMedGoogle Scholar
  42. Dupin, N., Rubin, V., De, C., et al. (1999). The influence of highly active antiretroviral therapy on AIDS-associated Kaposi’s sarcoma. Br J Dermatol 140(5), 875–881.PubMedGoogle Scholar
  43. Dupont, C., Vasseur, E., et al. (2000). Long-term efficacy on Kaposi’s sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients. CISIH 92. Centre d‘information et de soins de l‘immunodeficience humaine. AIDS 14(8), 987–993.PubMedGoogle Scholar
  44. Eltom, M. A., Jemal, A., et al. (2002). Trends in Kaposi’s sarcoma and non-Hodgkin’s lymphoma incidence in the United States from 1973 through 1998. J Natl Cancer Inst 94(16), 1204–1210.PubMedGoogle Scholar
  45. Engels, E. A., Atkinson, J. O., et al. (2007). Risk factors for human herpesvirus 8 infection among adults in the United States and evidence for sexual transmission. J Infect Dis 196(2), 199–207.PubMedGoogle Scholar
  46. Engels, E. A., Biggar, R. J., et al. (2003a). Detection and quantification of Kaposi’s sarcoma-associated herpesvirus to predict AIDS-associated Kaposi’s sarcoma. AIDS 17(12), 1847–1851.PubMedGoogle Scholar
  47. Engels, E. A., Biggar, R. J., et al. (2008). Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer 123(1), 187–194.PubMedGoogle Scholar
  48. Engels, E. A., Frisch, M., et al. (2003b). Re: “Estimation of risk of cancers before occurrence of acquired immunodeficiency syndrome in persons infected with human immunodeficiency virus”. Am J Epidemiol 157(10), 955; author reply 955–956.PubMedGoogle Scholar
  49. Engels, E. A., Pfeiffer, R. M., et al. (2006). Trends in cancer risk among people with AIDS in the United States 1980–2002. AIDS 20(12), 1645–1654.PubMedGoogle Scholar
  50. Fiorelli, V., Gendelman, R., et al. (1995). Cytokines from activated T cells induce normal endothelial cells to acquire the phenotypic and functional features of AIDS–Kaposi’s sarcoma spindle cells. J Clin Invest 95(4), 1723–1734.PubMedGoogle Scholar
  51. Fishman, D., Faulds, G., et al. (1998). The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 102(7), 1369–1376.PubMedGoogle Scholar
  52. Foster, C. B., Lehrnbecher, T., et al. (2000). An IL6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in men infected with human immunodeficiency virus. Blood 96(7), 2562–2567.PubMedGoogle Scholar
  53. French, M. A., Lenzo, N., et al. (2000). Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Med 1(2), 107–115.PubMedGoogle Scholar
  54. Ganem, D. (2006). KSHV infection and the pathogenesis of Kaposi’s sarcoma. Annu Rev Pathol 1, 273–296.PubMedGoogle Scholar
  55. Gaya, A., Esteve, A., et al. (2004). Amino acid residue at position 13 in HLA-DR beta chain plays a critical role in the development of Kaposi’s sarcoma in AIDS patients. AIDS 18(2), 199–204.PubMedGoogle Scholar
  56. Gazouli, M., Zavos, G., et al. (2004). The interleukin-6-174 promoter polymorphism is associated with a risk of development of Kaposi’s sarcoma in renal transplant recipients. Anticancer Res 24(2C), 1311–1314.PubMedGoogle Scholar
  57. Geddes, M., Franceschi, S., et al. (1995). Birthplace and classic Kaposi’s sarcoma in Italy. Associazione Italiana Registri Tumori. J Natl Cancer Inst 87(13), 1015–1017.PubMedGoogle Scholar
  58. Gill, J., Bourboulia, D., et al. (2002). Prospective study of the effects of antiretroviral therapy on Kaposi sarcoma–associated herpesvirus infection in patients with and without Kaposi sarcoma. J Acquir Immune Defic Syndr 31(4), 384–390.PubMedGoogle Scholar
  59. Goedert, J. J., Vitale, F., et al. (2002). Risk factors for classical Kaposi’s sarcoma. J Natl Cancer Inst 94(22), 1712–1718.PubMedGoogle Scholar
  60. Gras, L., Kesselring, A. M., et al. (2007). CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater. J Acquir Immune Defic Syndr 45(2), 183–192.PubMedGoogle Scholar
  61. Grossman, Z., Iscovich, J., et al. (2002). Absence of Kaposi sarcoma among Ethiopian immigrants to Israel despite high seroprevalence of human herpesvirus 8. Mayo Clin Proc 77(9), 905–909.PubMedGoogle Scholar
  62. Grulich, A. E., van Leeuwen, M. T., et al. (2007). Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 370(9581), 59–67.PubMedGoogle Scholar
  63. Gustafson, E. A., Schinazi, R. F., et al. (2000). Human herpesvirus 8 open reading frame 21 is a thymidine and thymidylate kinase of narrow substrate specificity that efficiently phosphorylates zidovudine but not ganciclovir. J Virol 74(2), 684–692.PubMedGoogle Scholar
  64. Guttman-Yassky, E., Cohen, A., et al. (2004). Familial clustering of classic Kaposi sarcoma. J Infect Dis 189(11), 2023–2026.PubMedGoogle Scholar
  65. Harrington, W., Jr., Sieczkowski, L., et al. (1997). Activation of HHV-8 by HIV-1 tat. Lancet 349(9054), 774–775.PubMedGoogle Scholar
  66. Haverkos, H. W., Pinsky, P. F., et al. (1985). Disease manifestation among homosexual men with acquired immunodeficiency syndrome: a possible role of nitrites in Kaposi’s sarcoma. Sex Transm Dis 12(4), 203–208.PubMedGoogle Scholar
  67. Hladik, W., Dollard, S. C., et al. (2003). Kaposi’s sarcoma in Uganda: risk factors for human herpesvirus 8 infection among blood donors. J Acquir Immune Defic Syndr 33(2), 206–210.PubMedGoogle Scholar
  68. Hoover, D. R., Black, C., et al. (1993). Epidemiologic analysis of Kaposi’s sarcoma as an early and later AIDS outcome in homosexual men. Am J Epidemiol 138(4), 266–278.PubMedGoogle Scholar
  69. Huang, L. M., Chao, M. F., et al. (2001). Reciprocal regulatory interaction between human herpesvirus 8 and human immunodeficiency virus type 1. J Biol Chem 276(16), 13427–13432.PubMedGoogle Scholar
  70. Hymes, K. B., Cheung, T., et al. (1981). Kaposi’s sarcoma in homosexual men-a report of eight cases. Lancet 2(8247), 598–600.PubMedGoogle Scholar
  71. Ioannidis, J. P., Skolnik, P. R., et al. (1995). Human leukocyte antigen associations of epidemic Kaposi’s sarcoma. AIDS 9(6), 649–651.PubMedGoogle Scholar
  72. Ishido, S., Wang, C., et al. (2000). Downregulation of major histocompatibility complex class I molecules by Kaposi’s sarcoma-associated herpesvirus K3 and K5 proteins. J Virol 74(11), 5300–5309.PubMedGoogle Scholar
  73. Jacobson, M. A., Zegans, M., et al. (1997). Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet 349(9063), 1443–1445.PubMedGoogle Scholar
  74. Kaloterakis, A., Papasteriades, C., et al. (1995). HLA in familial and nonfamilial Mediterranean Kaposi’s sarcoma in Greece. Tissue Antigens 45(2), 117–119.PubMedGoogle Scholar
  75. Karavellas, M. P., Plummer, D. J., et al. (1999). Incidence of immune recovery vitritis in cytomegalovirus retinitis patients following institution of successful highly active antiretroviral therapy. J Infect Dis 179(3), 697–700.PubMedGoogle Scholar
  76. Kaufmann, G. R., Perrin, L., et al. (2003). CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med 163(18), 2187–2195.PubMedGoogle Scholar
  77. Kestens, L., Melbye, M., et al. (1985). Endemic African Kaposi’s sarcoma is not associated with immunodeficiency. Int J Cancer 36(1), 49–54.PubMedGoogle Scholar
  78. Kimball, L. E., Casper, C., et al. (2004). Reduced levels of neutralizing antibodies to Kaposi sarcoma-associated herpesvirus in persons with a history of Kaposi sarcoma. J Infect Dis 189(11), 2016–2022.PubMedGoogle Scholar
  79. Laney, A. S., Cannon, M. J., et al. (2007). Human herpesvirus 8 presence and viral load are associated with the progression of AIDS-associated Kaposi’s sarcoma. AIDS 21(12), 1541–1545.PubMedGoogle Scholar
  80. Lanternier, F., Lebbe, C., et al. (2008). Kaposi’s sarcoma in HIV-negative men having sex with men. AIDS 22(10), 1163–1168.PubMedGoogle Scholar
  81. Lebbe, C., Blum, L., et al. (1998). Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi’s sarcoma. AIDS 12(7), F45–F49.PubMedGoogle Scholar
  82. Leidner, R. S., and Aboulafia, D. M. (2005). Recrudescent Kaposi’s sarcoma after initiation of HAART: a manifestation of immune reconstitution syndrome. AIDS Patient Care STDS 19(10), 635–644.PubMedGoogle Scholar
  83. Lifson, A. R., Darrow, W. W., et al. (1990a). Kaposi’s sarcoma in a cohort of homosexual and bisexual men. Epidemiology and analysis for cofactors. Am J Epidemiol 131(2), 221–231.PubMedGoogle Scholar
  84. Lifson, A. R., Darrow, W. W., et al. (1990b). Kaposi’s sarcoma among homosexual and bisexual men enrolled in the San Francisco City Clinic Cohort Study. J Acquir Immune Defic Syndr 3(Suppl 1), S32–S37.PubMedGoogle Scholar
  85. Lock, M. J., Thorley, N., et al. (2002). Azidodeoxythymidine and didehydrodeoxythymidine as inhibitors and substrates of the human herpesvirus 8 thymidine kinase. J Antimicrob Chemother 49(2), 359–366.PubMedGoogle Scholar
  86. Lorenzen, T., Albrecht, D., et al. (2002). HHV-8 DNA in blood and the development of HIV-associated Kaposi’s sarcoma in the era of HAART – a prospective evaluation. Eur J Med Res 7(6), 283–286.PubMedGoogle Scholar
  87. Marmor, M., Winchester, R., et al. (1995). Evidence for an effect of human leukocyte antigens on susceptibility to Kaposi’s sarcoma related to charge and peptide-binding properties of class I molecules. AIDS 9(10), 1194–1195.PubMedGoogle Scholar
  88. Martin, D. F., Kuppermann, B. D., et al. (1999). Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group. N Engl J Med 340(14), 1063–1070.PubMedGoogle Scholar
  89. Martin, J. N., Ganem, D. E., et al. (1998). Sexual transmission and the natural history of human herpesvirus 8 infection. N Engl J Med 338(14), 948–954.PubMedGoogle Scholar
  90. Maurer, T., Ponte, M., et al. (2007). HIV-associated Kaposi’s sarcoma with a high CD4 count and a low viral load. N Engl J Med 357(13), 1352–1353.PubMedGoogle Scholar
  91. Mbulaiteye, S. M., Biggar, R. J., et al. (2003). Immune deficiency and risk for malignancy among persons with AIDS. J Acquir Immune Defic Syndr 32(5), 527–533.PubMedGoogle Scholar
  92. McHardy, J., Williams, E. H., et al. (1984). Endemic Kaposi’s sarcoma: incidence and risk factors in the West Nile District of Uganda. Int J Cancer 33(2), 203–212.PubMedGoogle Scholar
  93. Merat, R., Amara, A., et al. (2002). HIV-1 infection of primary effusion lymphoma cell line triggers Kaposi’s sarcoma-associated herpesvirus (KSHV) reactivation. Int J Cancer 97(6), 791–795.PubMedGoogle Scholar
  94. Mocroft, A., Ledergerber, B., et al. (2003). Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 362(9377), 22–29.PubMedGoogle Scholar
  95. Mocroft, A., Youle, M., et al. (1996). Anti-herpesvirus treatment and risk of Kaposi’s sarcoma in HIV infection. Royal Free/Chelsea and Westminster Hospitals Collaborative Group. AIDS 10(10), 1101–1105.PubMedGoogle Scholar
  96. Montella, M., Franceschi, S., et al. (1996). Classic Kaposi’s sarcoma and volcanic soil in southern Italy. Lancet 347(9005), 905.PubMedGoogle Scholar
  97. Montesu, M. A., De Marco, R., et al. (1995). Soil silicates and Kaposi’s sarcoma in Sardinia. Lancet 346(8987), 1436–1437.PubMedGoogle Scholar
  98. Moore, R. D., and Keruly, J. C. (2007). CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis 44(3), 441–446.PubMedGoogle Scholar
  99. Murdoch, D. M., Venter, W. D., et al. (2008). Incidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in South Africa: a prospective study. AIDS 22(5), 601–610.PubMedGoogle Scholar
  100. Nawar, E., Mbulaiteye, S. M., et al. (2005). Risk factors for Kaposi’s sarcoma among HHV-8 seropositive homosexual men with AIDS. Int J Cancer 115(2), 296–300.PubMedGoogle Scholar
  101. Nguyen, H. Q., Magaret, A. S., et al. (2008). Persistent Kaposi sarcoma in the era of highly active antiretroviral therapy: characterizing the predictors of clinical response. AIDS 22(8), 937–945.PubMedGoogle Scholar
  102. Osmond, D. H., Buchbinder, S., et al. (2002). Prevalence of Kaposi sarcoma-associated herpesvirus infection in homosexual men at beginning of and during the HIV epidemic. J Am Med Assoc 287(2), 221–225.Google Scholar
  103. Paparizos, V. A., Kyriakis, K. P., et al. (2002). Response of AIDS-associated Kaposi sarcoma to highly active antiretroviral therapy alone. J Acquir Immune Defic Syndr 30(2), 257–258.PubMedGoogle Scholar
  104. Patel, P., Hanson, D. L., et al. (2008). Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992–2003. Ann Intern Med 148(10), 728–736.PubMedGoogle Scholar
  105. Pati, S., Pelser, C. B., et al. (2002). Antitumorigenic effects of HIV protease inhibitor ritonavir: inhibition of Kaposi sarcoma. Blood 99(10), 3771–3779.PubMedGoogle Scholar
  106. Pellet, C., Chevret, S., et al. (2001). Virologic and immunologic parameters that predict clinical response of AIDS-associated Kaposi’s sarcoma to highly active antiretroviral therapy. J Invest Dermatol 117(4), 858–863.PubMedGoogle Scholar
  107. Penn, I. (1996). Malignant melanoma in organ allograft recipients. Transplantation 61(2), 274–278.PubMedGoogle Scholar
  108. Pham, S. M., Kormos, R. L., et al. (1995). Solid tumors after heart transplantation: lethality of lung cancer. Ann Thorac Surg 60(6), 1623–1626.PubMedGoogle Scholar
  109. Piriou, E., Jansen, C. A., et al. (2005). Reconstitution of EBV latent but not lytic antigen-specific CD4+ and CD8+ T cells after HIV treatment with highly active antiretroviral therapy. J Immunol 175(3), 2010–2017.PubMedGoogle Scholar
  110. Pollack, M. S., Safai, B., et al. (1983). Frequencies of HLA and Gm immunogenetic markers in Kaposi’s sarcoma. Tissue Antigens 21(1), 1–8.PubMedGoogle Scholar
  111. Porter, K., Babiker, A., et al. (2003). Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet 362(9392), 1267–1274.PubMedGoogle Scholar
  112. Portsmouth, S., Stebbing, J., et al. (2003). A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi’s sarcoma. AIDS 17(11), F17–F22.PubMedGoogle Scholar
  113. Ratnam, I., Chiu, C., et al. (2006). Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort. Clin Infect Dis 42(3), 418–427.PubMedGoogle Scholar
  114. Righetti, E., Ballon, G., et al. (2002). Dynamics of Epstein–Barr virus in HIV-1-infected subjects on highly active antiretroviral therapy. AIDS 16(1), 63–73.PubMedGoogle Scholar
  115. Rizos, E., Drosos, A. A., et al. (2003). Isolated intraparotid Kaposi sarcoma in human immunodeficiency virus type 1 infection. Mayo Clin Proc 78(12), 1561–1563.PubMedGoogle Scholar
  116. Roithmaier, S., Haydon, A. M., et al. (2007). Incidence of malignancies in heart and/or lung transplant recipients: a single-institution experience. J Heart Lung Transplant 26(8), 845–849.PubMedGoogle Scholar
  117. Scala, G., Ruocco, M. R., et al. (1994). The expression of the interleukin 6 gene is induced by the human immunodeficiency virus 1 TAT protein. J Exp Med 179(3), 961–971.PubMedGoogle Scholar
  118. Sgadari, C., Barillari, G., et al. (2002). HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nat Med 8(3), 225–232.PubMedGoogle Scholar
  119. Shankaran, V., Ikeda, H., et al. (2001). IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410(6832), 1107–1111.PubMedGoogle Scholar
  120. Shelburne, S. A., Visnegarwala, F., et al. (2005). Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS 19(4), 399–406.PubMedGoogle Scholar
  121. Simonart, T., Van Vooren, J. P., et al. (1999). High incidence of Kaposi’s sarcoma in Iceland and the Faroe Islands. Br J Cancer 79(2), 373.PubMedGoogle Scholar
  122. Sirianni, M. C., Vincenzi, L., et al. (2002). NK cell activity controls human herpesvirus 8 latent infection and is restored upon highly active antiretroviral therapy in AIDS patients with regressing Kaposi’s sarcoma. Eur J Immunol 32(10), 2711–2720.PubMedGoogle Scholar
  123. Sitas, F., Bezwoda, W. R., et al. (1997). Association between human immunodeficiency virus type 1 infection and cancer in the black population of Johannesburg and Soweto, South Africa. Br J Cancer 75(11), 1704–1707.PubMedGoogle Scholar
  124. Sitas, F., Pacella-Norman, R., et al. (2000). The spectrum of HIV-1 related cancers in South Africa. Int J Cancer 88(3), 489–492.PubMedGoogle Scholar
  125. Smyth, M. J., Crowe, N. Y., et al. (2001). NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int Immunol 13(4), 459–463.PubMedGoogle Scholar
  126. Smyth, M. J., Thia, K. Y., et al. (2000). Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med 191(4), 661–668.PubMedGoogle Scholar
  127. Wabinga, H. R., Parkin, D. M., et al. (2000). Trends in cancer incidence in Kyadondo County, Uganda, 1960–1997. Br J Cancer 82(9), 1585–1592.PubMedGoogle Scholar
  128. Weir, A., and Wansbrough-Jones, M. (1997). Mucosal Kaposi’s sarcoma following protease inhibitor therapy in an HIV-infected patient. AIDS 11(15), 1895–1896.PubMedGoogle Scholar
  129. Whitby, D., Howard, M. R., et al. (1995). Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi’s sarcoma. Lancet 346(8978), 799–802.PubMedGoogle Scholar
  130. Zheng, N. N., McElrath, M. J., et al. (2007). Role of human immunodeficiency virus (HIV)-specific T-cell immunity in control of dual HIV-1 and HIV-2 infection. J Virol 81(17), 9061–9071.PubMedGoogle Scholar
  131. Ziegler, J., Newton, R., et al. (2003). Risk factors for Kaposi’s sarcoma: a case–control study of HIV-seronegative people in Uganda. Int J Cancer 103(2), 233–240.PubMedGoogle Scholar
  132. Ziegler, J. L. (1993). Endemic Kaposi’s sarcoma in Africa and local volcanic soils. Lancet 342(8883), 1348–1351.PubMedGoogle Scholar
  133. Ziegler, J. L., Newton, R., et al. (1997). Risk factors for Kaposi’s sarcoma in HIV-positive subjects in Uganda. AIDS 11(13), 1619–1626.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Department of MedicineUniversity of Washington School of MedicineSeattleUSA
  2. 2.Department of EpidemiologyUniversity of WashingtonSeattleUSA
  3. 3.Vaccine and Infectious Disease Institute, Fred Hutchinson Cancer Research CenterSeattleUSA

Personalised recommendations